Tests OriCAR-017 cell therapy in adults with relapsed or refractory multiple myeloma
Tests OriCAR-017, a CAR-T cell therapy, in adults with relapsed or refractory multiple myeloma.
Key facts
- Who runs it
- OriCell Therapeutics Co., Ltd.
- Where
- Atlanta, United StatesSee the site
- Trial code
- Registry title
- A Study to Evaluate the Safety, PK/PD of (OriCAR-017) in Subjects With RR/MM - RIGEL Study
- Status
- Recruiting
- Phase
- Phase 1
- People taking part
- 81 people, planned
- Started
- 3 Apr 2024
- Expected to end
- 12 Apr 2028
- Type of study
- Interventional
- Treatments tested
- OriCAR-017
- Record updated
- 2 August 2024
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults aged 18 to 75 with multiple myeloma that came back or stopped responding to treatment, and who have already had BCMA-directed therapy.
- Age
- 18 to 75 years
- Sex
- All sexes can join.
- Disease stage
- Multiple myeloma that has relapsed or does not respond to treatment, shown by M protein in blood or urine, abnormal free light chains, or lesions outside the bone marrow (more than 1 cm (0.4 in) across the short axis). Expected survival of more than 12 weeks.
- Earlier treatment
- Must have had earlier BCMA-directed therapy (such as teclistamab, BLENREP or BCMA-CAR-T). In the dose-escalation part, at least 3 prior lines of therapy and no response to the last line. Cannot have had an autologous stem cell transplant within 8 weeks, allogeneic stem cell therapy, or Bendamustine within 1 year before screening.
- Biomarker or test result
- Serum M protein above 10 g/L (IgG type) or above 5 g/L (IgA, IgD, IgE or IgM type); or urine M protein above 200 mg/24 hour; or serum free light chain above 100 mg/L with an abnormal K/λ ratio.
Main reasons for not taking part
- Pregnant or breastfeeding
- HIV positive, or active hepatitis B or hepatitis C
- Current or past involvement of the central nervous system
- Autoimmune disease that damaged organs or needed immune-suppressing drugs in the past 2 years
- Uncontrolled active infection
The registry criteria, word for word
Show all 22 criteriaShow less
Who can take part
- Capable of giving signed informed consent
- Subjects aged 18 to 75 years (inclusive) at Screening (signing the ICF)
- Expected survival period is >12 weeks
- Diagnosis of MM according to the IMWG criteria (2016 version)
- One of the following criteria must be met:
- If immunoglobulin (Ig)G type MM, then serum M protein >10 g/L; if IgA, IgD, IgE or IgM type MM, then serum M protein >5 g/L
- Urine M protein level >200 mg/24 hour
- If light chain type MM, then serum free light chain (sFLC) >100 mg/L and K/λ FLC ratio is abnormal
- Extramedullary lesions (>1 cm for diameter of the short axis)
- For Phase I (dose-escalation) - Subjects who had received at least 3 prior lines of therapy, had previous exposure to BCMA-Ag+ therapies, and were refractory to the last line of therapy
- For Phase I (dose-expansion) and Phase II: Subjects with previous exposure to BCMA directed therapies including BCMA bispecific antibody (e.g., teclistamab), BCMA antibody directed conjugate (such as BLENREP), and BCMA-CAR-T (such as CARVYKT1TM)
- Subjects with adequate hematologic, renal, hepatic, pulmonary and cardiac function
- Subject and partners willing to take and or use effective contraceptive measures until 2 years post IMP infusion
Who cannot take part
- Known active or prior history of CNS involvement
- Subjects who received autologous hematopoietic stem cell transplantation (ASCT) within 8 weeks of Screening Visit or who plan to undergo ASCT during the study
- Subjects who received allogeneic stem cell therapy
- Received Bendamustine treatment 1 year prior to Screening Visit
- Seropositive for history of human immunodeficiency virus Active Hepatitis B infection and or Hepatitis C infection
- History of autoimmune diseases (such as Crohn's disease, rheumatoid arthritis, systemic lupus erythematosus) caused damage to terminal organs or required systemic application of immunosuppressive or other drugs in the past 2 years
- Presence of uncontrolled active infection
- Any condition that in the opinion of the Investigator, would interfere with evaluation of the IMP
- Pregnant or breastfeeding
Check if you might fit
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 75 years old?
Where in United States
- Northside HospitalAtlanta, United StatesContact: Melhem SolhTaking people
About the trial
What the trial wants to find out
The is a first clinical study for Oricell Therapeutics Inc. in the United States to evaluate the safety, PK, PD and preliminary efficacy of our anti-GPRC5D cell product (OriCAR-017) in subjects with relapsed/refractory multiple myeloma.
Read full original descriptionShow less
RIGEL Study
The group in the trial
- OriCAR-017Treatment being tested
Single OriCAR-017 infusion
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- A Phase I/II, Open-label, Multicenter Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of Anti-GPRC5D CAR-T Cell Product (OriCAR-017) in Subjects With Relapsed/Refractory Multiple Myeloma.
- Plain-language title
- Tests OriCAR-017 cell therapy in adults with relapsed or refractory multiple myelomaGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Fit questions
- Built from NCT06271252, who can take part
- Record updated
- 2 August 2024